{"entity":{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","aka":[],"tldr":"A phase 1/2 trial of TUB-040 in ovarian cancer and non-small-cell lung cancer, run by Tubulis GmbH, now recruiting.","summary":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC is a phase 1/2 interventional study registered as NCT06303505 by Tubulis GmbH, with 250 participants planned, started 2024-06-12 and due to reach its primary completion in 2027-12. Interventions recorded: TUB-040.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06303505","url":"https://clinicaltrials.gov/study/NCT06303505"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06303505","phase":"1/2","setting":"A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)","sponsor":"Tubulis GmbH","enrolled":250,"outcomes":[]},"route":"/trials/nct06303505/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}]}}